The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 821
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Stakeholders
- Companies sponsors
- Chugai Pharma (anamorelin)
- Helsinn (anamorelin)
- Others
- Department of Health
- NHS England
- NHS Ipswich and East Suffolk CCG
- NHS Southwark CCG
- Welsh Government
- Patient carer groups
- Black Health Agency
- British Lung Foundation
- Cancer Black Care
- Cancer Equality
- HAWC
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- Muslim Council of Britain
- Roy Castle Lung Cancer Foundation
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- UK Lung Cancer Coalition
- Professional groups
- Association of Cancer Physicians
- Association of Respiratory Nurse Specialists
- British Dietetic Association
- British Geriatrics Society
- British Institute of Radiology
- British Psychosocial Oncology Society
- British Thoracic Oncology Group
- British Thoracic Society
- Cancer Research UK
- National Lung Cancer Forum for Nurses
- Primary Care Respiratory Society UK
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK Health Forum
- UK Oncology Nursing Society
- Associated public health groups
- Public Health England
- Public Health Wales
- General commentators
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare Products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Alliance
- NHS Commercial Medicines Unit
- NHS Confederation
- Scottish Medicines Consortium
- Relevant research groups
- Cochrane Lung Cancer Group
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 18 August 2022 | Discontinued. The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended. |
| 21 June 2017 | This appraisal has now been suspended and the appraisal committee discussion that was due to take place has been cancelled. This is due to an update on the regulatory status as the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, “recommending the refusal of the marketing authorisation for the medicinal product anamorelin intended for the treatment of anorexia, cachexia or unintended weight loss in patients with non-small cell lung cancer”. |
| 08 December 2016 | Invitation to participate |
| 08 June 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual